Skip to main content
Erschienen in: Intensive Care Medicine 2/2015

01.02.2015 | Original

Incidence, characteristics and outcome of ICU-acquired candidemia in India

verfasst von: Arunaloke Chakrabarti, Prashant Sood, Shivaprakash M. Rudramurthy, Sharon Chen, Harsimran Kaur, Malini Capoor, Deepinder Chhina, Ratna Rao, Vandana Kalwaje Eshwara, Immaculata Xess, Anupama J. Kindo, P. Umabala, Jayanthi Savio, Atul Patel, Ujjwayini Ray, Sangeetha Mohan, Ranganathan Iyer, Jagdish Chander, Anita Arora, Raman Sardana, Indranil Roy, B. Appalaraju, Ajanta Sharma, Anjali Shetty, Neelam Khanna, Rungmei Marak, Sanjay Biswas, Shukla Das, B. N. Harish, Sangeeta Joshi, Deepak Mendiratta

Erschienen in: Intensive Care Medicine | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

A systematic epidemiological study on intensive care unit (ICU)-acquired candidemia across India.

Method

A prospective, nationwide, multicentric, observational study was conducted at 27 Indian ICUs. Consecutive patients who acquired candidemia after ICU admission were enrolled during April 2011 through September 2012. Clinical and laboratory variables of these patients were recorded. The present study is an analysis of data specific for adult patients.

Results

Among 1,400 ICU-acquired candidemia cases (overall incidence of 6.51 cases/1,000 ICU admission), 65.2 % were adult. Though the study confirmed the already known risk factors for candidemia, the acquisition occurred early after admission to ICU (median 8 days; interquartile range 4–15 days), even infecting patients with lower APACHE II score at admission (median 17.0; mean ± SD 17.2 ± 5.9; interquartile range 14–20). The important finding of the study was the vast spectrum of agents (31 Candida species) causing candidemia and a high rate of isolation of Candida tropicalis (41.6 %). Azole and multidrug resistance were seen in 11.8 and 1.9 % of isolates. Public sector hospitals reported a significantly higher presence of the relatively resistant C. auris (8.2 vs. 3.9 %; p = 0.008) and C. rugosa (5.6 vs. 1.5 %; p = 0.001). The 30-day crude and attributable mortality rates of candidemia patients were 44.7 and 19.6 %, respectively. Logistic regression analysis revealed significant independent predictors of mortality including admission to public sector hospital, APACHE II score at admission, underlying renal failure, central venous catheterization and steroid therapy.

Conclusion

The study highlighted a high burden of candidemia in Indian ICUs, early onset after ICU admission, higher risk despite less severe physiology score at admission and a vast spectrum of agents causing the disease with predominance of C. tropicalis.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Meyer E, Geffers C, Gastmeier P et al (2013) No increase in primary nosocomial candidemia in 682 German intensive care units during 2006–2011. Euro Surveill 18(24):20505PubMed Meyer E, Geffers C, Gastmeier P et al (2013) No increase in primary nosocomial candidemia in 682 German intensive care units during 2006–2011. Euro Surveill 18(24):20505PubMed
2.
Zurück zum Zitat Gonzalez de Molina FJ, Leon C, Ruiz-Santana S et al (2012) Assessment of candidemia-attributable mortality in critically ill patients using propensity score matching analysis. Crit Care 16(3):R105PubMedCentralPubMedCrossRef Gonzalez de Molina FJ, Leon C, Ruiz-Santana S et al (2012) Assessment of candidemia-attributable mortality in critically ill patients using propensity score matching analysis. Crit Care 16(3):R105PubMedCentralPubMedCrossRef
3.
Zurück zum Zitat Nolla-Salas J, Sitges-Serra A, Leon-Gil C et al (1997) Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Study group of fungal infection in the ICU. Intensive Care Med 23(1):23–30PubMedCrossRef Nolla-Salas J, Sitges-Serra A, Leon-Gil C et al (1997) Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Study group of fungal infection in the ICU. Intensive Care Med 23(1):23–30PubMedCrossRef
4.
Zurück zum Zitat Charles PE, Doise JM, Quenot JP et al (2003) Candidemia in critically ill patients: difference of outcome between medical and surgical patients. Intensive Care Med 29(12):2162–2169PubMedCrossRef Charles PE, Doise JM, Quenot JP et al (2003) Candidemia in critically ill patients: difference of outcome between medical and surgical patients. Intensive Care Med 29(12):2162–2169PubMedCrossRef
5.
Zurück zum Zitat Guery BP, Arendrup MC, Auzinger G et al (2009) Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: part I. Epidemiology and diagnosis. Intensive Care Med 35(1):55–62PubMedCrossRef Guery BP, Arendrup MC, Auzinger G et al (2009) Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: part I. Epidemiology and diagnosis. Intensive Care Med 35(1):55–62PubMedCrossRef
6.
Zurück zum Zitat Lass-Florl C (2009) The changing face of epidemiology of invasive fungal disease in Europe. Mycoses 52(3):197–205PubMedCrossRef Lass-Florl C (2009) The changing face of epidemiology of invasive fungal disease in Europe. Mycoses 52(3):197–205PubMedCrossRef
7.
8.
Zurück zum Zitat Maubon D, Garnaud C, Calandra T et al (2014) Resistance of Candida spp. to antifungal drugs in the ICU: where are we now? Intensive Care Med 40(9):1241–1255PubMedCrossRef Maubon D, Garnaud C, Calandra T et al (2014) Resistance of Candida spp. to antifungal drugs in the ICU: where are we now? Intensive Care Med 40(9):1241–1255PubMedCrossRef
9.
Zurück zum Zitat CLSI (2008) Reference method for broth dilution antifungal susceptibility testing of yeasts, approved standard. CLSI document M27-A3, 3rd edn. Clinical and Laboratory Standards Institute (CLSI), Wayne, PA CLSI (2008) Reference method for broth dilution antifungal susceptibility testing of yeasts, approved standard. CLSI document M27-A3, 3rd edn. Clinical and Laboratory Standards Institute (CLSI), Wayne, PA
10.
Zurück zum Zitat CLSI (2012) Reference method for broth dilution antifungal susceptibility testing of yeasts, fourth informational supplement. CLSI document M27-S4. Clinical and Laboratory Standards Institute, Wayne, PA CLSI (2012) Reference method for broth dilution antifungal susceptibility testing of yeasts, fourth informational supplement. CLSI document M27-S4. Clinical and Laboratory Standards Institute, Wayne, PA
11.
Zurück zum Zitat Playford EG, Marriott D, Nguyen Q et al (2008) Candidemia in nonneutropenic critically ill patients: risk factors for non-albicans Candida spp. Crit Care Med 36(7):2034–2039PubMedCrossRef Playford EG, Marriott D, Nguyen Q et al (2008) Candidemia in nonneutropenic critically ill patients: risk factors for non-albicans Candida spp. Crit Care Med 36(7):2034–2039PubMedCrossRef
12.
Zurück zum Zitat Leroy G, Lambiotte F, Thevenin D et al (2011) Evaluation of Candida score in critically ill patients: a prospective, multicenter, observational, cohort study. Ann Intensive Care 1(1):50PubMedCentralPubMedCrossRef Leroy G, Lambiotte F, Thevenin D et al (2011) Evaluation of Candida score in critically ill patients: a prospective, multicenter, observational, cohort study. Ann Intensive Care 1(1):50PubMedCentralPubMedCrossRef
13.
Zurück zum Zitat Kett DH, Azoulay E, Echeverria PM et al (2011) Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study. Crit Care Med 39(4):665–670PubMedCrossRef Kett DH, Azoulay E, Echeverria PM et al (2011) Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study. Crit Care Med 39(4):665–670PubMedCrossRef
14.
Zurück zum Zitat Bassetti M, Merelli M, Righi E et al (2013) Epidemiology, species distribution, antifungal susceptibility, and outcome of candidemia across five sites in Italy and Spain. J Clin Microbiol 51(12):4167–4172PubMedCentralPubMedCrossRef Bassetti M, Merelli M, Righi E et al (2013) Epidemiology, species distribution, antifungal susceptibility, and outcome of candidemia across five sites in Italy and Spain. J Clin Microbiol 51(12):4167–4172PubMedCentralPubMedCrossRef
15.
Zurück zum Zitat Chow JK, Golan Y, Ruthazer R et al (2008) Risk factors for albicans and non-albicans candidemia in the intensive care unit. Crit Care Med 36(7):1993–1998PubMedCrossRef Chow JK, Golan Y, Ruthazer R et al (2008) Risk factors for albicans and non-albicans candidemia in the intensive care unit. Crit Care Med 36(7):1993–1998PubMedCrossRef
16.
Zurück zum Zitat Leroy O, Gangneux JP, Montravers P et al (2009) Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005–2006). Crit Care Med 37(5):1612–1618PubMedCrossRef Leroy O, Gangneux JP, Montravers P et al (2009) Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005–2006). Crit Care Med 37(5):1612–1618PubMedCrossRef
17.
Zurück zum Zitat Pappas PG, Rex JH, Lee J et al (2003) A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 37(5):634–643PubMedCrossRef Pappas PG, Rex JH, Lee J et al (2003) A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 37(5):634–643PubMedCrossRef
19.
Zurück zum Zitat Leroy O, Mira JP, Montravers P et al (2010) Comparison of albicans vs. non-albicans candidemia in French intensive care units. Crit Care 14(3):R98PubMedCentralPubMedCrossRef Leroy O, Mira JP, Montravers P et al (2010) Comparison of albicans vs. non-albicans candidemia in French intensive care units. Crit Care 14(3):R98PubMedCentralPubMedCrossRef
20.
Zurück zum Zitat Pfaller MA, Messer SA, Moet GJ et al (2011) Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in intensive care unit (ICU) and non-ICU settings in the SENTRY antimicrobial surveillance program (2008–2009). Int J Antimicrob Agents 38(1):65–69PubMedCrossRef Pfaller MA, Messer SA, Moet GJ et al (2011) Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in intensive care unit (ICU) and non-ICU settings in the SENTRY antimicrobial surveillance program (2008–2009). Int J Antimicrob Agents 38(1):65–69PubMedCrossRef
21.
Zurück zum Zitat White MH (1997) The contribution of fluconazole to the changing epidemiology of invasive candidal infections. Clin Infect Dis 24(6):1129–1130PubMedCrossRef White MH (1997) The contribution of fluconazole to the changing epidemiology of invasive candidal infections. Clin Infect Dis 24(6):1129–1130PubMedCrossRef
22.
Zurück zum Zitat Lortholary O, Renaudat C, Sitbon K et al (2014) Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002–2010). Intensive Care Med 40(9):1303–1312PubMedCentralPubMedCrossRef Lortholary O, Renaudat C, Sitbon K et al (2014) Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002–2010). Intensive Care Med 40(9):1303–1312PubMedCentralPubMedCrossRef
23.
Zurück zum Zitat Chakrabarti A, Chatterjee SS, Rao KL et al (2009) Recent experience with fungaemia: change in species distribution and azole resistance. Scand J Infect Dis 41(4):275–284PubMedCrossRef Chakrabarti A, Chatterjee SS, Rao KL et al (2009) Recent experience with fungaemia: change in species distribution and azole resistance. Scand J Infect Dis 41(4):275–284PubMedCrossRef
24.
Zurück zum Zitat Mootsikapun P, Hsueh PR, Talwar D et al (2013) Intravenous anidulafungin followed optionally by oral voriconazole for the treatment of candidemia in Asian patients: results from an open-label phase III trial. BMC Infect Dis 13:219PubMedCentralPubMedCrossRef Mootsikapun P, Hsueh PR, Talwar D et al (2013) Intravenous anidulafungin followed optionally by oral voriconazole for the treatment of candidemia in Asian patients: results from an open-label phase III trial. BMC Infect Dis 13:219PubMedCentralPubMedCrossRef
25.
Zurück zum Zitat Fournier P, Schwebel C, Maubon D et al (2011) Antifungal use influences Candida species distribution and susceptibility in the intensive care unit. J Antimicrob Chemother 66(12):2880–2886PubMedCrossRef Fournier P, Schwebel C, Maubon D et al (2011) Antifungal use influences Candida species distribution and susceptibility in the intensive care unit. J Antimicrob Chemother 66(12):2880–2886PubMedCrossRef
26.
Zurück zum Zitat Blot S, Janssens R, Claeys G et al (2006) Effect of fluconazole consumption on long-term trends in candidal ecology. J Antimicrob Chemother 58(2):474–477PubMedCrossRef Blot S, Janssens R, Claeys G et al (2006) Effect of fluconazole consumption on long-term trends in candidal ecology. J Antimicrob Chemother 58(2):474–477PubMedCrossRef
27.
Zurück zum Zitat Lockhart SR, Messer SA, Gherna M et al (2009) Identification of Candida nivariensis and Candida bracarensis in a large global collection of Candida glabrata isolates: comparison to the literature. J Clin Microbiol 47(4):1216–1217PubMedCentralPubMedCrossRef Lockhart SR, Messer SA, Gherna M et al (2009) Identification of Candida nivariensis and Candida bracarensis in a large global collection of Candida glabrata isolates: comparison to the literature. J Clin Microbiol 47(4):1216–1217PubMedCentralPubMedCrossRef
28.
Zurück zum Zitat Leon C, Ostrosky-Zeichner L, Schuster M (2014) What’s new in the clinical and diagnostic management of invasive candidiasis in critically ill patients. Intensive Care Med 40(6):808–819PubMedCrossRef Leon C, Ostrosky-Zeichner L, Schuster M (2014) What’s new in the clinical and diagnostic management of invasive candidiasis in critically ill patients. Intensive Care Med 40(6):808–819PubMedCrossRef
29.
Zurück zum Zitat Blot SI, Vandewoude KH, Hoste EA et al (2002) Effects of nosocomial candidemia on outcomes of critically ill patients. Am J Med 113(6):480–485PubMedCrossRef Blot SI, Vandewoude KH, Hoste EA et al (2002) Effects of nosocomial candidemia on outcomes of critically ill patients. Am J Med 113(6):480–485PubMedCrossRef
30.
Zurück zum Zitat Nucci M, Anaissie E, Betts RF et al (2010) Early removal of central venous catheter in patients with candidemia does not improve outcome: analysis of 842 patients from 2 randomized clinical trials. Clin Infect Dis 51(3):295–303PubMedCrossRef Nucci M, Anaissie E, Betts RF et al (2010) Early removal of central venous catheter in patients with candidemia does not improve outcome: analysis of 842 patients from 2 randomized clinical trials. Clin Infect Dis 51(3):295–303PubMedCrossRef
31.
Zurück zum Zitat Gudlaugsson O, Gillespie S, Lee K et al (2003) Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 37(9):1172–1177PubMedCrossRef Gudlaugsson O, Gillespie S, Lee K et al (2003) Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 37(9):1172–1177PubMedCrossRef
32.
Zurück zum Zitat Das I, Nightingale P, Patel M et al (2011) Epidemiology, clinical characteristics, and outcome of candidemia: experience in a tertiary referral center in the UK. Int J Infect Dis 15(11):e759–e763PubMedCrossRef Das I, Nightingale P, Patel M et al (2011) Epidemiology, clinical characteristics, and outcome of candidemia: experience in a tertiary referral center in the UK. Int J Infect Dis 15(11):e759–e763PubMedCrossRef
33.
Zurück zum Zitat Colombo AL, Guimaraes T, Sukienik T et al (2014) Prognostic factors and historical trends in the epidemiology of candidemia in critically ill patients: an analysis of five multicenter studies sequentially conducted over a 9-year period. Intensive Care Med 40(10):1489–1498PubMedCentralPubMedCrossRef Colombo AL, Guimaraes T, Sukienik T et al (2014) Prognostic factors and historical trends in the epidemiology of candidemia in critically ill patients: an analysis of five multicenter studies sequentially conducted over a 9-year period. Intensive Care Med 40(10):1489–1498PubMedCentralPubMedCrossRef
Metadaten
Titel
Incidence, characteristics and outcome of ICU-acquired candidemia in India
verfasst von
Arunaloke Chakrabarti
Prashant Sood
Shivaprakash M. Rudramurthy
Sharon Chen
Harsimran Kaur
Malini Capoor
Deepinder Chhina
Ratna Rao
Vandana Kalwaje Eshwara
Immaculata Xess
Anupama J. Kindo
P. Umabala
Jayanthi Savio
Atul Patel
Ujjwayini Ray
Sangeetha Mohan
Ranganathan Iyer
Jagdish Chander
Anita Arora
Raman Sardana
Indranil Roy
B. Appalaraju
Ajanta Sharma
Anjali Shetty
Neelam Khanna
Rungmei Marak
Sanjay Biswas
Shukla Das
B. N. Harish
Sangeeta Joshi
Deepak Mendiratta
Publikationsdatum
01.02.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Intensive Care Medicine / Ausgabe 2/2015
Print ISSN: 0342-4642
Elektronische ISSN: 1432-1238
DOI
https://doi.org/10.1007/s00134-014-3603-2

Weitere Artikel der Ausgabe 2/2015

Intensive Care Medicine 2/2015 Zur Ausgabe

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Ärztliche Empathie hilft gegen Rückenschmerzen

23.04.2024 Leitsymptom Rückenschmerzen Nachrichten

Personen mit chronischen Rückenschmerzen, die von einfühlsamen Ärzten und Ärztinnen betreut werden, berichten über weniger Beschwerden und eine bessere Lebensqualität.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.